Giuseppe
Emeritus
Vaccine. 2008 Sep 16. [Epub ahead of print]
Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model.
Murakami S, Iwasa A, Iwatsuki-Horimoto K, Ito M, Kiso M, Kida H, Takada A, Nidom CA, Mai LQ, Yamada S, Imai H, Sakai-Tagawa Y, Kawaoka Y, Horimoto T. - Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
H5N1 highly pathogenic avian influenza viruses evolved into several clades, leading to appreciably distinct antigenicities of their hemagglutinins.
As such, candidate H5N1 pre-pandemic vaccines for human use should be sought.
Here, to evaluate fundamental immunogenic variations between H5N1 vaccines, we prepared four inactivated H5N1 test vaccines from different phylogenetic clades (clade 1, 2.1, 2.2, and 2.3.4) in accordance with the WHO recommendation, and tested their cross-clade immunity in a mouse model by vaccination followed by challenge with heterologous virulent viruses.
All H5N1 vaccines tested provided full or partial cross-clade protective immunity, except one clade 2.2-based vaccine, which did not protect mice from clade 2.3.4 virus challenge.
Among the test vaccines, a clade 2.1-based vaccine possessed the broadest-spectrum cross-immunity.
These results suggest that currently stockpiled pre-pandemic vaccines, especially clade 2.1-based vaccines, will likely be useful as backup vaccines in a pandemic situation, even one involving antigenic-drifted viruses.
-
PMID: 18804131 [PubMed - as supplied by publisher
------
Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model.
Murakami S, Iwasa A, Iwatsuki-Horimoto K, Ito M, Kiso M, Kida H, Takada A, Nidom CA, Mai LQ, Yamada S, Imai H, Sakai-Tagawa Y, Kawaoka Y, Horimoto T. - Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
H5N1 highly pathogenic avian influenza viruses evolved into several clades, leading to appreciably distinct antigenicities of their hemagglutinins.
As such, candidate H5N1 pre-pandemic vaccines for human use should be sought.
Here, to evaluate fundamental immunogenic variations between H5N1 vaccines, we prepared four inactivated H5N1 test vaccines from different phylogenetic clades (clade 1, 2.1, 2.2, and 2.3.4) in accordance with the WHO recommendation, and tested their cross-clade immunity in a mouse model by vaccination followed by challenge with heterologous virulent viruses.
All H5N1 vaccines tested provided full or partial cross-clade protective immunity, except one clade 2.2-based vaccine, which did not protect mice from clade 2.3.4 virus challenge.
Among the test vaccines, a clade 2.1-based vaccine possessed the broadest-spectrum cross-immunity.
These results suggest that currently stockpiled pre-pandemic vaccines, especially clade 2.1-based vaccines, will likely be useful as backup vaccines in a pandemic situation, even one involving antigenic-drifted viruses.
-
PMID: 18804131 [PubMed - as supplied by publisher
------